- Home
- NRDS vs CSTL Comparison
NRDS vs CSTL Comparison
Compare NRDS & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRDS
- CSTL
- Stock Information
- Founded
- NRDS 2009
- CSTL 2007
- Country
- NRDS United States
- CSTL United States
- Employees
- NRDS 650
- CSTL N/A
- Industry
- NRDS EDP Services
- CSTL Medical Specialities
- Sector
- NRDS Technology
- CSTL Health Care
- Exchange
- NRDS Nasdaq
- CSTL Nasdaq
- Market Cap
- NRDS 616.0M
- CSTL 568.2M
- IPO Year
- NRDS 2021
- CSTL 2019
- Fundamental
- Price
- NRDS $8.54
- CSTL $21.51
- Analyst Decision
- NRDS Buy
- CSTL Strong Buy
- Analyst Count
- NRDS 5
- CSTL 6
- Target Price
- NRDS $17.00
- CSTL $40.00
- AVG Volume (30 Days)
- NRDS 540.9K
- CSTL 330.2K
- Earning Date
- NRDS 04-28-2025
- CSTL 05-05-2025
- Dividend Yield
- NRDS N/A
- CSTL N/A
- EPS Growth
- NRDS N/A
- CSTL N/A
- EPS
- NRDS 0.38
- CSTL 0.62
- Revenue
- NRDS $687,600,000.00
- CSTL $332,069,000.00
- Revenue This Year
- NRDS $12.65
- CSTL N/A
- Revenue Next Year
- NRDS $8.37
- CSTL $3.34
- P/E Ratio
- NRDS $22.47
- CSTL $34.69
- Revenue Growth
- NRDS 14.71
- CSTL 51.09
- 52 Week Low
- NRDS $7.55
- CSTL $16.97
- 52 Week High
- NRDS $16.45
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- NRDS 43.07
- CSTL 56.26
- Support Level
- NRDS $8.18
- CSTL $18.03
- Resistance Level
- NRDS $8.92
- CSTL $20.77
- Average True Range (ATR)
- NRDS 0.55
- CSTL 1.27
- MACD
- NRDS 0.08
- CSTL 0.41
- Stochastic Oscillator
- NRDS 46.26
- CSTL 93.06
About NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides onsumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.